SCHEMBL12901470

SCHEMBL12901470

CC(C)(C)OC(=O)N1CCC[C@@]2(CC(Br)=NO2)C1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
USP30 Q70CQ3 1/20 0.40
GPR119 Q8TDV5 1/20 0.39
HPGD P15428 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SCD5 Q86SK9 1/20 0.36
CYP11B2 P19099 1/20 0.35
NAMPT P43490 1/20 0.35
PIK3R1 P27986 3/20 0.35
PIK3CA P42336 3/20 0.35
MMP2 P08253 1/20 0.35
MMP13 P45452 1/20 0.35
MMP14 P50281 1/20 0.35
ADAM17 P78536 1/20 0.35
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12901471 1.00 USP2 (0.40) USP2SMN1; SMN2USP30GPR119HPGD
SCHEMBL12901444 1.00 USP2 (0.40) USP2SMN1; SMN2USP30GPR119HPGD
SCHEMBL12901472 0.93 GPR119 (0.45) USP2SMN1; SMN2GPR119SCD5CYP11B2
SCHEMBL12901445 0.93 GPR119 (0.45) USP2SMN1; SMN2GPR119SCD5CYP11B2
SCHEMBL12901473 0.93 GPR119 (0.45) USP2SMN1; SMN2GPR119SCD5CYP11B2
SCHEMBL12901476 0.91 GPR119 (0.46) USP2SMN1; SMN2USP30GPR119HPGD
SCHEMBL12901443 0.91 GPR119 (0.46) USP2SMN1; SMN2USP30GPR119HPGD
SCHEMBL12901475 0.91 GPR119 (0.46) USP2SMN1; SMN2USP30GPR119HPGD
SCHEMBL16056006 0.87 USP2 (0.43) USP2SMN1; SMN2GPR119HPGDRECQL
SCHEMBL12901469 0.86 GPR119 (0.49) USP2SMN1; SMN2GPR119RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150099738-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2015-04-09 US disclosed
US-20150099738-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2015-04-09 US disclosed
US-8765735-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765735-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-20110034437-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-10 US disclosed
US-20110034437-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034437-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, HRH2 USP2 725/4885SMN1; SMN2 4142/4885USP30 657/4885
US-20150099738-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, HRH2 USP2 725/4885SMN1; SMN2 4142/4885USP30 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.